Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US

Leah J McGrath¹
Robert A Overman¹
Diane Reams¹
Karynsa Cetin²
Alexander Liede³
Steven A Narod⁴
M Alan Brookhart¹
Rohini K Hernandez²

¹NoviSci, LLC, Durham, NC, USA; ²Amgen Inc, Thousand Oaks, CA, USA; ³Amgen Inc, South San Francisco, CA, USA; ⁴Department of Medicine, University of Toronto, Toronto, Canada

Purpose: Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the use of BMAs (denosumab and intravenous bisphosphonates) among women in the US.

Patients and methods: Electronic health records from oncology clinics were used to identify women diagnosed with bone metastasis from breast cancer between 2013 and 2014. Patients were excluded if they had recently used a BMA or had concurrent cancer at an additional primary site. The incidence of BMA initiation, interruption, and reinitiation were estimated using competing risk regression models. A generalized linear model was used to estimate risk factors for treatment initiation and interruption.

Results: There were 589 women diagnosed with bone metastasis from breast cancer. By 1 year, 68% of these patients (95% CI: 64%, 71%) had initiated treatment with a BMA. Denosumab and zoledronic acid were the most commonly used agents, whereas pamidronate was used infrequently. Young women were more likely to initiate a BMA than older women (adjusted risk difference: 6.4 [95% CI: 1.5, 10.9]). Of the 412 patients who initiated a BMA, 46% (95% CI: 41%, 51%) experienced an interruption within 1 year. Seventy-four percent (95% CI: 68%, 79%) of patients who interrupted their treatment had reinitiated therapy within 1 year of interruption.

Conclusion: The majority of women diagnosed with bone metastasis from breast cancer initiate a BMA within 1 year of diagnosis, but a large proportion, particularly among the elderly, do not use these therapies.

Keywords: bone-modifying agents, breast cancer, bone metastasis, treatment patterns, electronic health records, denosumab, zoledronic acid, pamidronate

Introduction

Each year, there are approximately 266,000 new cases of female breast cancer in the US.¹ The bone is the most common site of distant metastasis for women with breast cancer.² Depending on the study and the time period evaluated,³ approximately 15% of new breast cancer patients (40,000 cases) are expected to develop bone metastases during the course of their disease.⁴,⁵ Not only is this typically a sign of the incurable nature of the underlying disease, but metastatic bone disease is also associated with serious skeletal complications. These are collectively referred to as skeletal-related events (SREs) and include severe bone pain (often requiring radiation), pathological fractures, bone instability requiring surgery, and spinal cord compression.⁶ SREs are associated with severe pain,⁷ elevated mortality risk,⁸ and increased health care costs.⁹
Nearly 40% of patients with bone metastases from breast cancer experience an SRE within 1 year of developing bone metastasis.\textsuperscript{10}

Three therapies are currently approved in the US for the prevention of SREs in breast cancer patients with bone metastases. Pamidronate, a nitrogen-containing bisphosphonate (approved in 1991), is administered intravenously over a 2-hour period every 3–4 weeks.\textsuperscript{11} Zoledronic acid, a bisphosphonate (approved in 2001), is administered intravenously over a 15-minute infusion every 3–4 weeks.\textsuperscript{12} Denosumab, a monoclonal antibody with affinity for the receptor activator of nuclear factor-kappa ligand (approved in 2010), is administered subcutaneously every 4 weeks.\textsuperscript{13} These agents can reduce the risk of occurrence of SREs, and thereby improve the quality of life and functional independence.\textsuperscript{14–17} Oral bisphosphonates are not currently recommended to prevent SREs in this population.

Current clinical guidelines recommend bone-modifying agents (BMAs) for breast cancer patients with bone metastases,\textsuperscript{13,19} but little is known about how often these therapies are used in routine care in the US. We examined real-world data from electronic health records (EHRs) supplemented with important unstructured, clinical data abstracted through medical chart review to measure the initiation, interruption, and reinitiation of three BMAs among women with bone metastasis from breast cancer. We also examined the factors associated with initiation and treatment interruption.

\textbf{Materials and methods}

\textbf{Data source}

We conducted a retrospective cohort study using the Flatiron Health Analytic Database. While these data are not freely available, they may be purchased and used by researchers after all necessary data use agreements are executed. The database incorporates information from 255 cancer clinics (at community-based practices and two academic centers) and 2,330 clinicians across the US, and includes more than 1.3 million active cancer patients. Flatiron provides rich, real-world clinical data generated from the EHR systems routinely used by cancer care providers.\textsuperscript{20} The EHR captures longitudinal information on clinical diagnoses, medication administrations (including dose), laboratory results, and biomarkers. The data include both structured (ie, drop-down fields in the EHR that capture a patient’s sex or date of birth) and unstructured data (ie, free text from a physician’s note or laboratory report). Flatiron uses validated, technology-enabled chart abstraction\textsuperscript{21} followed by a manual review of unstructured data elements. In this study, the diagnoses of bone metastasis and SREs were validated using the unstructured data.

\textbf{Study design}

We identified a cohort of adult women with breast cancer (ICD-9 174.x, 175.x or ICD-10 C50.xx) who had a bone metastasis documented within 10 years after the breast cancer diagnosis and within the time period January 1, 2013 through December 31, 2014. A clinic visit was required in the period from 180 days before to 30 days after the date of diagnosis of the bone metastasis to ensure active enrollment in the Flatiron EHR data system. Patients were excluded if they had received denosumab, pamidronate, or zoledronic acid in the 6-month period before the diagnosis of bone metastasis or if they had an additional non-melanoma cancer at a primary site in the 12-month period prior to the diagnosis of bone metastasis.

We created three nested cohorts of patients to examine the cumulative incidence of BMA initiation, interruption, and reinitiation. First, initiation was evaluated among all breast cancer patients with bone metastasis, and was defined as a first administration of denosumab, zoledronic acid, or pamidronate. The index date (ie, when follow-up began) was 30 days after the date of bone metastasis diagnosis to allow for the assessment of the inclusion criterion requiring activity in Flatiron. Second, the interruption of a BMA was evaluated among all patients who initiated a BMA, and was defined as any 45-day interval that included a health care encounter but did not include the intravenous or subcutaneous administration of a BMA. A 45-day interval was chosen to capture the recommended administration time window for BMAs (once per 28 days) plus a short grace period. The index date was the date of BMA initiation. The date of interruption was imputed as the date of the last BMA administration plus 45 days. Third, treatment reinitiation was evaluated among all patients who had experienced a treatment interruption. This was defined as the first BMA administration following an interruption. The index date was the imputed date of interruption.

For all analyses, patients were followed until the earliest of the following events: the outcome of interest (initiation, interruption, reinitiation), end of health care (defined as 90 days without a health care encounter), and death or the end of study (June 30, 2016).

\textbf{Statistical analysis}

We identified covariates using the structured and unstructured data and assessed baseline characteristics prior to the date of bone metastasis. These characteristics were updated at the start of follow-up for each nested cohort. For example,
for patients who initiated a BMA and who were followed for a treatment interruption, baseline characteristics were assessed at the date of the BMA initiation. Baseline covariates were defined during the 6-month baseline period or using all available data before the index date to identify chronic comorbidities. Baseline laboratory tests and functional status (measured by the Eastern Cooperative Oncology Group Performance Status [ECOG]) were defined in the 60 days before the diagnosis of bone metastasis. The estimated glomerular filtration rate (eGFR) was calculated using serum creatinine levels and the Chronic Kidney Disease Epidemiology Collaboration equation.\(^2\) If there were multiple test results or ECOG measurements during that period, the result closest to the index date was used. Other medications of interest (eg, chemotherapy) were defined during the 30 days prior to the index date. Time-varying covariates were identified: 1) during the 30-day period following the diagnosis of bone metastasis and during each 30-day interval thereafter (for predictors of treatment initiation); and 2) during the 45-day period following treatment initiation and during each 45-day interval thereafter (for predictors of treatment interruption).

We computed descriptive statistics for baseline covariates. The cumulative incidence of initiation, interruption, and reinstitution was calculated using Fine–Gray models that accounted for the competing risk of death.\(^2\) These models were stratified by BMA type and calendar year of bone metastasis diagnosis. To assess the risk factors of initiation and interruption, follow-up was discretized into 30-day intervals for initiation and 45-day intervals for interruption. Treatments, comorbidities, and laboratory results were updated within each interval. If laboratory results were missing in a given interval, the last-observation-carried-forward method was used to impute laboratory information for that interval. We estimated the absolute difference in monthly risk of each outcome using multivariable repeated measures generalized models with an identity link function to estimate risk differences. All measured variables were included in the models. Asymptotically correct 95% CIs were obtained using a nonparametric bootstrap. Predictors of each outcome were drawn from the interval prior to the interval in which the outcome occurred, as well as from all prior intervals and the baseline period. Patients only contributed to a specific interval thereafter (for predictors of treatment interruption).

Results

There were 920 women initially identified in the Flatiron database who were diagnosed with bone metastases from breast cancer for whom a medical chart abstraction was completed. After applying study eligibility criteria, there were 589 women remaining, of whom 45% were 65 years and older, 60% were White, 91% had stage II or higher breast cancer when diagnosed, and 12% had a history of pathologic fracture (Table 1). The prevalence of biomarkers was as follows: 83% estrogen receptor-positive, 70% progesterone receptor-positive, 21% human epidermal growth factor receptor 2 (HER2)-positive, and 10% triple-negative (negative for all three receptors). During follow-up, 412 women initiated treatment with a BMA, and 258 experienced a subsequent treatment interruption after initiation (Table 1). Compared with the overall cohort measured at the diagnosis of bone metastasis, the demographic and biomarker characteristics of patients who initiated and interrupted BMA treatment were similar, although the prevalence of a history of pathologic fracture was higher (21% and 25% at initiation and interruption, respectively), indicating that patients were experiencing SREs during follow-up (Table 1).

Initiation

Of the 589 women indicated for BMA therapy, the cumulative incidence of treatment initiation after the diagnosis of bone metastasis was 32% (95% CI: 28%, 35%) at 30 days, 64% (95% CI: 60%, 67%) at 180 days, and 68% (95% CI: 64%, 71%) at 1 year (Figure 1A). The usage of denosumab and zoledronic acid was similar; the cumulative incidence at 90 days was 28% for denosumab and 27% for zoledronic acid. However, there was a small difference between the drugs when stratified by calendar year of bone metastasis diagnosis. Zoledronic acid was used more frequently than denosumab in 2013 (1 year incidence: 33% vs 30%), while denosumab was used more frequently in 2014 (1 year incidence: 38% vs 32%; data not shown), indicating a possible shift in treatment patterns over time.

Factors that were positively associated with the use of a BMA included young age and white race. Younger patients were more likely to initiate treatment compared to older women (adjusted risk difference [aRD]: 6.4; 95% CI: 1.5, 10.9), and White patients were more likely to initiate treatment compared to Black patients (aRD: 6.5; 95% CI: 2.8, 10.2). Patients with lower functional status (>1 on ECOG assessment), low albumin, HER2-positive status, and metastases to other sites (not including the lung, brain, and lymph...
| Variable                                      | Women with bone metastases from breast cancer | Subset who initiated BMA treatment | Subset who interrupted BMA treatment |
|-----------------------------------------------|-----------------------------------------------|----------------------------------|-------------------------------------|
|                                               | N     | %    | N     | %    | N     | %    |
| Total                                         | 589   | 100  | 412   | 100  | 258   | 100  |
| Year of index date                            |       |      |       |      |       |      |
| 2013                                          | 290   | 49.2 | 160   | 38.8 | 43    | 16.7 |
| 2014                                          | 299   | 50.8 | 221   | 53.6 | 101   | 39.1 |
| 2015                                          | –     | –    | 29    | 7.0  | 98    | 38.0 |
| 2016                                          | –     | –    | 2     | 0.5  | 16    | 6.2  |
| Age (years)                                   |       |      |       |      |       |      |
| 18–39                                         | 29    | 4.9  | 22    | 5.3  | 14    | 5.4  |
| 40–49                                         | 79    | 13.4 | 52    | 12.6 | 34    | 13.2 |
| 50–64                                         | 215   | 36.5 | 153   | 37.6 | 99    | 38.4 |
| 65+                                           | 266   | 45.2 | 183   | 44.4 | 111   | 43.0 |
| Race                                          |       |      |       |      |       |      |
| White                                         | 356   | 60.4 | 261   | 63.3 | 166   | 64.3 |
| Black                                         | 60    | 10.2 | 34    | 8.3  | 24    | 9.3  |
| Asian                                         | 14    | 2.4  | 10    | 2.4  | 9     | 3.5  |
| Other                                         | 88    | 14.9 | 55    | 13.3 | 34    | 13.2 |
| Missing                                       | 71    | 12.1 | 52    | 12.6 | 25    | 9.7  |
| History of SREs                               |       |      |       |      |       |      |
| Pathological fracture                         | 72    | 12.2 | 86    | 20.9 | 66    | 25.6 |
| Spinal cord compression                       | 9     | 1.5  | 7     | 1.7  | 5     | 1.9  |
| External beam radiation therapy               | 9     | 1.5  | 87    | 21.1 | 92    | 35.7 |
| Bone surgery                                  | 19    | 3.2  | 24    | 5.8  | 24    | 9.3  |
| Other sites of metastases                    |       |      |       |      |       |      |
| Lung                                          | 69    | 11.7 | 72    | 17.5 | 25    | 9.7  |
| Brain                                         | 15    | 2.5  | 21    | 5.1  | 16    | 6.2  |
| Distant lymph node                            | 47    | 8     | 67    | 16.3 | 24    | 9.3  |
| Prior cancer treatment                        |       |      |       |      |       |      |
| Chemotherapy                                  | 21    | 3.6  | 151   | 36.7 | 101   | 39.1 |
| Colony-stimulating factor                     | 14    | 2.4  | 47    | 11.4 | 43    | 16.7 |
| Hormonal therapy                              | 73    | 12.4 | 216   | 52.4 | 97    | 37.6 |
| Renal disease                                 | 86    | 14.6 | 109   | 26.5 | 79    | 30.6 |
| eGFR (mL/min)                                 |       |      |       |      |       |      |
| <60                                           | 32    | 5.4  | 34    | 8.3  | 21    | 8.1  |
| ≥60                                           | 121   | 20.5 | 110   | 26.7 | 73    | 28.3 |
| Missing                                       | 436   | 74    | 268   | 65.0 | 164   | 63.6 |
| ER status                                     |       |      |       |      |       |      |
| Positive                                      | 490   | 83.2 | 353   | 85.7 | 221   | 85.7 |
| Negative                                      | 93    | 15.8 | 58    | 14.1 | 37    | 14.3 |
| Unknown                                       | 6     | 1     | 1     | 0.2  | 0     | 0.0  |
| PR status                                     |       |      |       |      |       |      |
| Positive                                      | 410   | 69.6 | 296   | 71.8 | 195   | 75.6 |
| Negative                                      | 167   | 28.4 | 110   | 26.7 | 60    | 23.3 |
| Unknown                                       | 12    | 2     | 6     | 1.5  | 3     | 1.2  |
| HER2 status                                   |       |      |       |      |       |      |
| Positive                                      | 122   | 20.7 | 78    | 18.9 | 55    | 21.3 |
| Negative                                      | 443   | 75.2 | 323   | 78.4 | 198   | 76.7 |
| Unknown/equivocal                             | 24    | 4.1  | 11    | 2.7  | 5     | 1.9  |
| Insurance payer                               |       |      |       |      |       |      |
| Commercial health insurance plan              | 137   | 23.3 | 102   | 24.8 | 69    | 26.7 |
| Medicaid                                      | 18    | 3.1  | 12    | 2.9  | 8     | 3.1  |
| Medicare                                      | 25    | 4.2  | 10    | 2.4  | 5     | 1.9  |
| Missing                                       | 132   | 22.4 | 89    | 21.6 | 40    | 15.5 |
| Multiple                                      | 192   | 32.6 | 140   | 34.0 | 97    | 37.6 |
| Other                                         | 85    | 14.4 | 59    | 14.3 | 38    | 14.7 |

**Notes:** Baseline characteristics were measured in the 6-month baseline period or using all available data prior to the index date to identify chronic comorbidities. Baseline characteristics were updated at the start of BMA treatment and on the date of BMA interruption. “–” indicates that there were zero patients in this category.

**Abbreviations:** BMA, bone-modifying agent; eGFR, estimated glomerular filtration rate; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SRE, skeletal-related event.
nodes) were less likely to initiate treatment (Figure 2A). Additionally, patients with an eGFR <30 mL/min were less likely to start zoledronic acid (aRD: –12.6; 95% CI: –18.3, –7.1) and more likely to initiate denosumab (aRD: 23.9; 95% CI: 12.5, 35.3) compared to patients with higher eGFR values. Patients with Medicaid and Medicare were less likely to initiate treatment with a BMA, particularly with denosumab (Medicare aRD: –23.3; 95% CI: –28.8, –17.4), compared to those with a commercial health insurance plan; although this finding is based on a relatively small sample of patients with Medicare insurance. Finally, women taking hormonal therapy for their cancer treatment were more likely to initiate denosumab (aRD: 7.3; 95% CI: 5.0, 9.4) and less likely to initiate zoledronic acid (aRD: –2.6; 95% CI: –4.5, –0.5).

**Interruption and reinitiation**

Of the 412 women who initiated a BMA, 46% had a treatment interruption in the first year (95% CI: 41%, 51%) (Figure 1B). The frequencies of interruption of denosumab and zoledronic acid were similar; at 90 days, 19% and 16% of patients taking denosumab and zoledronic acid, respectively, experienced an interruption. Interruption of treatment with
either BMA was more likely among patients with low serum albumin and patients with a history of metastasis to other non-bone sites and slightly more likely for patients on chemotherapy (Figure 2B). Only 9.5% of patients experiencing a treatment interruption (N=84) died within 60 days of stopping BMA therapy.

Of the 258 patients who interrupted their BMA therapy, 74% (95% CI: 68%, 79%) reinitiated treatment with the same

**Figure 2** Adjusted risk difference estimates per 100 for variables associated with bone-modifying agent initiation (A) and interruption (B).

**Note:** Each estimate in the model was adjusted for all other variables listed as well as alkaline phosphatase level and serum calcium level.

**Abbreviations:** ECOG, Eastern Cooperative Oncology Group Performance Status; eGFR, estimated glomerular filtration rate; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SRE, skeletal-related event.

| A) Initiation |
| --- |
| 18–39 vs 65+ |
| 40–49 vs 65+ |
| 50–64 vs 65+ |
| White vs Black |
| Asian vs Black |
| Medicaid vs commercial |
| Medicare vs commercial |
| Multiple payer vs commercial |

| B) Interruption |
| --- |
| Demographics |
| Underweight |
| Overweight |
| Obese |
| Cancer stage: 0/I vs IV |
| Cancer stage: II/III vs IV |
| ECOG, 1 vs 0 |
| ECOG, >1 vs 0 |
| Any SRE |
| Lung metastasis |
| Brain metastasis |
| Lymph node metastasis |
| Other metastasis |
| Hypocalcemia (<9.1 mg/dL) |
| Low albumin (<3.5 g/dL) |
| eGFR, <30 vs ≥60 mL/min |
| eGFR, 30–59 vs ≥60 mL/min |
| Chemotherapy |
| Hormonal therapy |
| Colony-stimulating factor |
| ER-positive |
| PR-positive |
| HER2-positive |
| Triple-negative |

---

1354  \[\text{submit your manuscript | www.dovepress.com} \]

Dovepress  \[\text{Clinical Epidemiology 2018:10} \]
BMA (Figure 1B), with a median of 18 days (minimum, 1 day; maximum, 402 days) following interruption. The incidence of reinitiation was higher in denosumab patients compared to zoledronic acid patients (80% vs 69% at 1 year, respectively). The number of patients who had a treatment interruption followed by a reinitiation was too small to draw conclusions about the factors associated with reinitiation.

**Discussion**

Women with breast cancer metastatic to the bone may be candidates for treatment with a BMA for the prevention of SREs. SREs compromise the quality of life, and in some cases, can be fatal. BMAs are used for patients with skeletal metastases alone or with distant metastases at other sites.

In our study of women receiving care at community-based oncology clinics in the US, about one-third of patients with bone metastasis from breast cancer did not receive treatment with a BMA, and there was substantial variation in the timing of initiation for women who did initiate treatment. Among those who started a BMA, about half experienced an interruption by 1 year. However, most patients who experienced a treatment interruption later reinitiated the same type of therapy.

The estimate of BMA initiation in our analysis (68% at 1 year) was similar to a study using administrative health care claims data, which showed that 67% (Medicare) and 58% (commercial health insurance plan) of prevalent breast cancer patients with bone metastasis received a BMA in 2012. However, this study focused on prevalent patients rather than incident patients, did not validate bone metastasis, and did not account for censoring. The shift in the type of BMA treatment administered over time was also seen in other solid tumor types, including breast, prostate, and lung. Qian et al. showed that zoledronic acid was favored in 2012 and 2013, but denosumab was administered more frequently in 2014. The incidence of BMA treatment was lower in our study compared to a large, multicenter cohort study in Germany, where 89% of patients with advanced breast cancer and bone metastasis initiated a BMA. However, a similar distribution between types of drugs was seen; zoledronic acid and denosumab were used almost equally. Finally, a study conducted in men with prostate cancer and bone metastasis in routine care in the US showed that BMAs were used at slightly higher rates in this population (77% at 1 year), although incidence of treatment interruption (54% at 1 year) and reinitiation (81% at 1 year) were similar.

Younger women were more likely to initiate a BMA compared to older women. Older patients likely represent a frailler population with more complex medical regimens and moderate-to-severe comorbidity status. Prior studies have also shown less aggressive treatment patterns for older breast cancer patients. Similarly, Black women were much more likely to initiate BMAs compared to Black women. A similar pattern was observed in a study examining hormonal therapy. However, Black women in our study represented a small proportion of the study population (10%).

Patients who were HER2-positive were less likely to initiate treatment compared to those who were HER2-negative. This finding may reflect that HER2-positive breast cancer is more aggressive, more likely to involve lymph nodes, and more likely to recur, which may require more complex treatment. Therefore, physicians may be disinclined to initiate non-chemotherapy medications used for supportive care in this population in an effort to reduce the complexity of managing the underlying disease. Several studies have shown that patients who are sicker or show evidence of frailty do not receive preventive therapies.

Patients with Medicaid and Medicare were much less likely to initiate BMAs, particularly denosumab, compared to those with a commercial health insurance plan, although this finding was based on a relatively small sample of patients with Medicare or Medicaid. It is possible that cost could represent a barrier to use, particularly among patients receiving complex and expensive breast cancer treatments.

Renal disease was a common comorbidity in the population at baseline, and its prevalence increased during follow-up. Patients with an eGFR <30 mL/min were less likely to start zoledronic acid and more likely to initiate denosumab compared to those with higher eGFR values. This finding likely reflects the contraindicated use of zoledronic acid in those with an eGFR <30 mL/min. Although denosumab should also be used with caution in those with renal dysfunction, it is the preferred agent in this population due to the limited evidence of renal toxicity. Renal disease may also be a factor in treatment interruption. While renal disease was not shown to be a predictor of treatment interruption, 31% of patients who had an interruption of any type of BMA treatment had renal disease at some time prior to the interruption.

In this study, we used a 45-day period without treatment to define a treatment interruption; the recommended dosing window for BMAs during the time period of this study was once per 28 days, and we added a short grace period to that dosing schedule. It is possible that dosing patterns could have been influenced by ongoing clinical trials at the time. Specifically, the ZOOM trial (conducted in Italy) and the OPTIMIZE-2 trial (conducted in the US) both showed
that zoledronic acid dosing every 12 weeks was noninferior
to dosing every 4 weeks. However, the ZOOM trial was
not published until June 2013 and the OPTIMIZE-2 trial
was published in 2017. The calendar years of our study
(2013–2014) may have been too early to reflect changes in
treatment regimens in routine clinical care. Indeed, further
examination of dosing regimens among this cohort revealed
that very few (<2%) patients initiating denosumab showed
evidence of an extended dosing window (ie, Q4 dosing for 6
months followed by Q12 dosing; unpublished data).

Although guidelines recommend the use of denosumab
or intravenous bisphosphonates as soon as bone metastases
are definitively diagnosed in women with breast cancer, there
is limited evidence on the optimal treatment duration.39 This
is not something that can be determined from large pivotal
trials because the life expectancy of patients with metastatic
breast cancer involving the bone may approach or exceed the
median length of follow-up in these studies.40–42 For some
women with skeletal metastases from breast cancer, life span
can be relatively long, exceeding 5 years in 12.5% of the
cases;4 thus, these women may be at risk of experiencing a
bone complication for several years after their diagnosis of
bone metastases. Along with the potential long-term benefits
of the drugs, clinicians must also consider the risk of adverse
events, including osteonecrosis of the jaw and hypocalcemia.
In a recent meta-analysis, denosumab was associated with
increased risk of grade 3 or 4 hypocalcemia (relative risk:
1.99; 95% CI: 1.11, 3.54) in comparison to intravenous
bisphosphonates, due to denosumab’s powerful antiresorptive
effect and reduced risk of renal impairment or toxicity (relative
risk: 0.75; 95% CI: 0.61, 0.91) in comparison to intra-
venous bisphosphonates.40 The rates of osteonecrosis of the
jaw can be higher for individuals treated with antiresorptives
for longer durations.41 Health care providers should discuss
the risks and benefits of BMA therapy with the patients with
breast cancer who have metastatic bone disease.

There are several limitations that should be considered
when interpreting the results of this study. Our study used
EHRs primarily from community-based oncology clinics, and
therefore, our results may not be generalizable to other cancer
treatment settings because of the limited number of academic
centers in the database. Additionally, the EHR systems from
oncology centers likely do not fully capture the presence and
timing of comorbidities unrelated to cancer care. Indeed, in
the present study, the prevalence of chronic comorbidities
was substantially lower than what would be expected in this
population, and therefore, we were unable to comprehensively
assess how these variables relate to BMA treatment initiation
or interruption. We were unable to capture detailed clinical
information on bone metastasis (eg, number, location) or
dental disease or procedures, both of which could be associ-
ated with treatment initiation. Furthermore, delays in BMA
treatment initiation could be due to ensuring that patients have
dental exams, radiographs, and completion of invasive dental
procedures prior to starting BMA treatment,18,43,44 or delays
could occur while obtaining insurance approval; however, we
were unable to differentiate between these in the data. Finally,
although laboratory results and functional status (measured via
ECOG assessment) were available in the database, they were
missing for a large proportion of the population. For example,
79% of the population did not have ECOG measurements dur-
ing the initiation baseline period. The amount of missing data
in these variables decreased with follow-up. Thus, because we
treated these variables as time-dependent, we enhanced capture
of this information throughout the follow-up.

In summary, based on the data collected in routine clini-
cal practice in the US, approximately one-third of women
with bone metastasis from breast cancer do not initiate
BMA therapy. Furthermore, among women who do initiate
treatment, duration may be suboptimal. Additional studies
to further understand the reasons for these observed trends
(eg, preferences of the patient or treating clinician), whether
altered dosing guidelines changed treatment patterns in later
years, as well as the consequences of remaining untreated
or experiencing interruptions in treatment, are warranted.

Acknowledgment

This study was funded by Amgen Inc.

Disclosure

RKH, KC, and AL are employees of Amgen Inc and have
stock ownership in Amgen Inc. MAB has had research sup-
port from Amgen and AstraZeneca, owns equity in NoviSci,
LLC, and has served as a scientific advisor/consultant to
Amgen, Merck, TargetPharma, Genentech, AbbVie, and
RxAnte, LLC. LJM, RAO, DR, and SAN have no potential
conflicts of interest to report in this work.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J
Clin. 2018;68(1):7–30.
2. Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases
of metastatic bone disease in the US adult population. Clin Epidemiol.
2012;4:87–93.
3. Zhang H, Zhu W, Biskup E, et al. Incidence, risk factors and prognostic
characteristics of bone metastases and skeletal-related events (SREs)
in breast cancer patients: A systematic review of the real world data.
J Bone Oncol. 2018;11:38–50.
4. Lieb A, Jezzark KJ, Hernandez RK, Wade SW, Sun P, Narod SA. The incidence of bone metastasis after early-stage breast cancer in Canada. *Breast Cancer Res Treat*. 2016;156(3):587–595.
5. Hernandez RK, Wade SW, Reich A, Prollo M, Lieb A, Lyman GH. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. *BMC Cancer*. 2018;18(1):44.
6. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res*. 2006;12(20 Pt 2):6235–6249.
7. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. *Br J Cancer*. 2005;92(10):1869–1876.
8. Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006. *Breast Cancer Res Treat*. 2012;131(1):231–238.
9. Hagiwara M, Delea TE, Chung K. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases. *J Med Econ*. 2014;17(3):223–230.
10. Jensen AO, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. *BMC Cancer*. 2011;11:29.
11. Pamidronate Disodium [prescribing information]. Bedford, OH: Bedford Laboratories; 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf. Accessed August 27, 2018.
12. Zometa [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016. Available from: https://www.novartis.us/sites/www.pharma.us.novartis.com/files/Zometa.pdf. Accessed August 27, 2018.
13. XGEVA [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2017. Available from: http://pi.amgen.com/-/media/amgen/repository-sites/pi-amgen-com/xgeva/xgeva_pi_ashx. Accessed August 27, 2018.
14. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. *Cochrane Database Syst Rev*. 2012;2:Cd003474.
15. Ford J, Jones R, Elders A, et al. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. *Eur J Cancer*. 2013;49(2):416–430.
16. Hatoum HT, Lin SJ, Smith MR. Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. *Cancer*. 2008;113(6):1438–1445.
17. Hatoum HT, Lin SJ, Smith MR, Guo A, Lipton A. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. *Clin Breast Cancer*. 2011;11(3):177–183.
18. van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. *J Clin Oncol*. 2011;29(9):1221–1227.
19. Grazul JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health In Cancer Care. *J Natl Compr Canc Netw*. 2011;11 Suppl 3:S1–S9; quiz S51.
20. Flatiron Health. Available from: https://flatiron.com/real-world-evidence/. Accessed August 27, 2018.
21. Lieb A, Hernandez RK, Roth M, Calkins G, Larrahke K, Nicacio L. Validation of International Classification of Diseases codes for bone metastases in electronic health records using technology-enabled abstraction. *Clin Epidemiol*. 2015;7:441–448.
22. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604–612.
23. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J Am Stat Assoc*. 1999;94(446):496–509.
24. *R: A Language and Environment for Statistical Computing* [computer program]. Vienna: R Foundation for Statistical Computing; 2017.
25. Hernandez RK, Adhia A, Wade SW, et al. Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. *Clin Epidemiol*. 2015;7:335–345.
26. Qian Y, Bowmik D, Chakru N, Hernandez RK. Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. *Support Care Cancer*. 2017;25(6):1845–1851.
27. Schroder J, Fietz T, Kohler A, et al. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study. *Eur J Cancer*. 2017;79:139–148.
28. Butler AM, Cetin K, Hernandez RK, et al. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States. *Pharmcoepidemiol Drug Saf*. 2018;27(2):229–238.
29. Eaker S, Dickman PW, Bergkvist L, Holmborg L, Uppsala-Orebro Breast Cancer Group. Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. *PLoS Med*. 2006;3(3):e25.
30. Enger SM, Thwin SS, Buist DS, et al. Breast cancer treatment of older women in integrated health care settings. *J Clin Oncol*. 2006;24(27):4377–4383.
31. Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. *J Clin Oncol*. 2007;25(14):1858–1869.
32. Eshghi A, Anzali VB, Faul LA, Luta G, et al. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. *J Clin Oncol*. 2014;32(22):2318–2327.
33. Burstein HJ. The distinctive nature of HER2-positive breast cancers. *N Engl J Med*. 2005;353(16):1652–1654.
34. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. *Epidemiology*. 2001;12(6):682–689.
35. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. *N Engl J Med*. 1998;338(21):1516–1520.
36. Jackson LA, Nelson JC, Bennon P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. *Int J Epidemiol*. 2006;35(2):345–352.
37. Amador D, Aglietta M, Alessi B, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. *Lancet Oncol*. 2013;14(7):663–670.
38. Himelstein AL, Foster JC, Khatcherressian JL, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. *JAMA*. 2017;317(1):48–58.
39. van Poznak C, Somerfield MR, Barlow WE, et al. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. *J Clin Oncol*. 2017;35(35):3978–3986.
40. Menshawy A, Mattar O, Abdulkarim A, et al. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. *Support Care Cancer*. 2018;26(4):1029–1038.
41. Stopeck AT, Fizzali K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. *Support Care Cancer*. 2016;24(1):447–455.
42. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol*. 2010;28(35):5132–5139.
43. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. *J Oral Maxillofac Surg*. 2014;72(10):1938–1956.
44. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res*. 2015;30(1):3–23.
